Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15445855 | 0.88 | BRD4 (0.42) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| SCHEMBL4463171 | 0.88 | BRD4 (0.42) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| SCHEMBL17756080 | 0.88 | BRD4 (0.42) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| Bicarbonate SCHEMBL7356898 | 0.84 | BRD4 (0.40) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| Ethylene SCHEMBL11701928 | 0.81 | BRD4 (0.43) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| SCHEMBL791232 | 0.80 | BRD4 (0.46) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| Ethylene SCHEMBL11226332 | 0.79 | TP53 (0.52) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 | |
| Ethylene SCHEMBL27716391 | 0.79 | — | — | |
| SCHEMBL16388414 | 0.78 | HTT (0.32) | SMN1; SMN2KMT2A | |
| SCHEMBL2948892 | 0.78 | TP53 (0.56) | TP53SMN1; SMN2BRD4CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8398887-B2 | Liquid crystal compounds of butylenes | YANTAI VALIANT FINE CHEMICALS CO., LTD. (CN) | 2013-03-19 | — | — | US | disclosed |
| US-20110260106-A1 | LIQUID CRYSTAL COMPOUNDS OF BUTYLENES | VALIANT CORPORATION LIMITED (CN) | 2011-10-27 | — | — | US | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110260106-A1 | LIQUID CRYSTAL COMPOUNDS OF BUTYLENES | OR10J3, CNOT1, MYB | TP53 3494/4885SMN1; SMN2 2079/4885BRD4 684/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | TP53 3461/4885SMN1; SMN2 2768/4885BRD4 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.